Carlsmed (NASDAQ:CARL) Given New $26.00 Price Target at BTIG Research

Carlsmed (NASDAQ:CARL) had its price objective lifted by analysts at BTIG Research from $24.00 to $26.00 in a report released on Wednesday, Benzinga reports. The firm currently has a “buy” rating on the stock. BTIG Research‘s price objective would indicate a potential upside of 76.75% from the company’s current price.

A number of other research analysts have also weighed in on CARL. Truist Financial raised their price objective on Carlsmed from $18.00 to $20.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. Wall Street Zen raised Carlsmed from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Carlsmed in a report on Wednesday, November 4th. Finally, Needham & Company LLC raised their price target on Carlsmed from $17.00 to $22.00 and gave the company a “buy” rating in a report on Wednesday. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $21.25.

Carlsmed Price Performance

Shares of Carlsmed stock opened at $14.71 on Wednesday. The company has a debt-to-equity ratio of 0.18, a current ratio of 8.84 and a quick ratio of 8.66. The business’s 50 day simple moving average is $14.87 and its two-hundred day simple moving average is $12.52. The stock has a market capitalization of $401.58 million, a P/E ratio of -10.29 and a beta of 1.97. Carlsmed has a one year low of $8.50 and a one year high of $17.23.

Carlsmed (NASDAQ:CARL) last released its quarterly earnings data on Tuesday, November 10th. The company reported ($0.34) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.08. The firm had revenue of $21.55 million during the quarter. Carlsmed had a negative return on equity of 38.06% and a negative net margin of 57.42%. Analysts forecast that Carlsmed will post -1.50 EPS for the current year.

Hedge Funds Weigh In On Carlsmed

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CARL. Deutsche Bank AG purchased a new stake in Carlsmed during the 2nd quarter valued at $106,000. Bank of America Corp DE purchased a new position in shares of Carlsmed in the second quarter worth $108,000. Alpine Woods Capital Investors LLC purchased a new position in shares of Carlsmed in the second quarter worth $161,000. Bank of New York Mellon Corp purchased a new position in shares of Carlsmed in the second quarter worth $181,000. Finally, Zevenbergen Capital Investments LLC lifted its holdings in shares of Carlsmed by 50.4% during the third quarter. Zevenbergen Capital Investments LLC now owns 17,900 shares of the company’s stock valued at $252,000 after purchasing an additional 6,000 shares in the last quarter.

About Carlsmed

Carlsmed, Inc. is a medical technology company focused on personalized solutions for spine surgery. The company combines patient-specific planning, advanced imaging, software and additive manufacturing to develop implants designed to address the anatomical needs of individual patients. Its products include the aprevo® patient-specific interbody implant system, which is designed for use in spinal fusion procedures. Carlsmed’s technology is intended to support surgeons in planning procedures and selecting or creating implants that may help restore spinal alignment and improve surgical precision.